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ORIGINAL INVESTIGATION
Sodium-glucose cotransporter 2 inhibitors 
(SGLT2i) and cardiac arrhythmias: a systematic 
review and meta-analysis
Hang‑Long Li1,6, Gregory‑Y. H. Lip2,3, Qi Feng4, Yue Fei5, Yi‑Kei Tse1, Mei‑zhen Wu1,6, Qing‑wen Ren1,6, 
Hung‑Fat Tse1,6, Bernard‑M. Y. Cheung5 and Kai‑Hang Yiu1,6*  
Abstract 
Background: Cardiac arrhythmias are associated with poorer outcomes in patients with heart failure (HF), diabetes 
mellitus (DM), and chronic kidney disease (CKD). Previous studies have shown inconsistent conclusions regarding the 
association between sodium‑glucose cotransporter 2 inhibitors (SGLT2i) and the risk of developing arrhythmias. This 
study aims to investigate the association of SGLT2i treatment with arrhythmia outcomes in clinical trials of patients 
with HF, DM, or CKD.
Methods: MEDLINE, EMBASE, and ClinicalTrials.gov were searched from inception up to 27 August 2020. Rand‑
omized controlled trials that randomized patients with DM, CKD, or HF to SGLT2i or placebo were included. The out‑
comes of interest include atrial fibrillation (AF), embolic stroke, atrial flutter (AFL), AF/AFL, ventricular tachycardia (VT), 
and cardiac arrest. Relative risks (RRs) and 95% confidence intervals (CI) were pooled using a random‑effects model.
Results: Out of 4,532 citations, 22 trials with altogether 52,115 patients were included (mean age 63.2 years; 33,747 
[64.8%] of participants were men). SGLT2i were associated with a lower risk of AF (RR 0.82, 95% CI 0.70–0.96), embolic 
stroke (RR 0.32, 95% CI 0.12–0.85), AF/AFL (RR 0.82, 95% CI 0.71–0.95), and VT (RR 0.73, 95% CI 0.53–0.99), while the 
risk reductions in AFL (RR 0.83, 95% CI 0.58–1.17) and cardiac arrest (RR 0.83, 95% CI 0.61–1.14) did not reach statisti‑
cal significance. The associations appeared to be consistent across different baseline conditions (DM vs CKD vs HF; 
atherosclerotic cardiovascular disease [ASCVD] vs no ASCVD) and the SGLT2i used.
Conclusions: SGLT2i reduced the risk of cardiac arrhythmias. Our study provides further evidence for recommending 
the use of SGLT2i in patients with DM, CKD, and HF. Further research is needed to fully elucidate the mechanism by 
which SGLT2i protect against arrhythmias.
Keywords: SGLT2 inhibitors, Arrhythmia, Atrial fibrillation
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Background
Diabetes mellitus (DM) and related comorbidities 
including heart failure (HF), obesity, hypertension, and 
chronic kidney disease (CKD) are closely linked to atrial 
fibrillation (AF) [1–5]. These conditions are associated 
with myocardial fibrosis and remodeling, neurohormonal 
activation, autonomic dysfunction, and electrical remod-
eling, predisposing to the development of AF and cardiac 
arrhythmias [2–6]. As AF and dysrhythmias are associ-
ated with a higher risk of adverse cardiovascular events 
and death, it is important to reduce the risk of cardiac 
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Sodium-glucose cotransporter 2 inhibitors (SGLT2i) 
are antidiabetic medications which act by inhibiting 
the reabsorption of sodium and glucose in the proxi-
mal tubules of the kidney [13]. Commonly used SGLT2i 
include canagliflozin, dapagliflozin, and empagliflozin 
[13]. The cardioprotective effects of SGLT2i have been 
increasingly recognized in recent years: studies have 
shown that SGLT2i protected against atherosclerotic 
cardiovascular disease (ASCVD) and reduced HF hos-
pitalization [13–15]. Furthermore, studies have shown 
that SGLT2i promoted weight loss and lowered blood 
pressure [13, 16]. In view of the wide spectrum of car-
diovascular benefits, it has been hypothesized that 
SGLT2i may reduce the risk of AF and cardiac arrhyth-
mias [17].
However, the associations between SGLT2i and AF 
remained inconsistent across previous studies. A recent 
secondary analysis of the DECLARE-TIMI 58 trial 
(Dapagliflozin Effect on Cardiovascular Events-Throm-
bolysis in Myocardial Infarction 58) found that dapa-
gliflozin reduced the risk of AF and atrial flutter (AFL) 
by 19% in susceptible patients with DM, compared to 
placebo [17]. The reduction in AF/AFL events was 
consistent regardless of the presence of ASCVD, HF, 
and AF at baseline. However, one previous meta-anal-
ysis did not identify a significant association between 
SGLT2i and AF [18]. In the EMPA-REG OUTCOME 
trial (Empagliflozin Cardiovascular Outcome Event 
Trial in Type 2 Diabetes Mellitus Patients), the empa-
gliflozin arm had a higher incidence of new-onset AF 
(2.3%) compared to the placebo arm (1.6%), though 
it was not an adjudicated outcome of the trial [19]. 
Recent real-world studies have also shown inconsistent 
conclusions: while SGLT2i were associated with a lower 
incidence of new-onset arrhythmias and AF, [20, 21] 
the CVD-REAL Nordic study [22] showed neutral asso-
ciation. Other types of arrhythmias, such as ventricular 
tachycardia (VT), as well as related conditions such as 
cardiac arrest, have been less well studied. Hence, the 
association between SGLT2i and arrhythmia outcomes 
remains uncertain.
Therefore, the objective of this systematic review and 
meta-analysis was to evaluate the effects of SGLT2i on 
common arrhythmia outcomes (AF, AFL, VT, and car-
diac arrest) and related complications (embolic stroke) in 
patients with DM, CKD, and HF.
Methods
This systematic review and meta-analysis was conducted 
and reported according to the Cochrane Handbook (Ver-
sion 5.1.0) [23] and the PRISMA statement [24]. The 
PRISMA checklist is shown in Additional file 1: Table S1.
Data sources and searches
Ovid MEDLINE, Ovid EMBASE, and ClinicalTrials.gov 
were searched for eligible studies through 27 August 
2020. The search strategy is shown in Additional file  1: 
Table  S2. Reviews articles and expert consensus state-
ments were also manually searched for eligible studies.
Study selection
We included RCTs that compared SGLT2i with placebo 
in adult patients (≥ 18 years) with type 2 DM, CKD, or 
HF and reported outcomes of interest as serious adverse 
events (SAEs). In order to ascertain the true anti-arrhyth-
mic effects of SGLT2i, trials that randomized patients 
to combination therapy were excluded, and placebo was 
selected as a comparator. There were no restrictions on 
follow-up duration or the language of publication. The 
outcomes of interest include AF, embolic stroke, AFL, 
AF/AFL, VT, and cardiac arrest. Titles and abstracts were 
first screened to assess their potential eligibility, followed 
by full-text examination to determine final eligibility.
Data extraction and quality assessment
The following information was extracted using a pre-
specified data extraction form: bibliographic information 
(First author, year of publication), study information (trial 
name, ClinicalTrials.gov unique identifier, country, sam-
ple size), patients characteristics (age, proportion of male 
patients, baseline conditions and comorbidities (DM, 
CKD, HF, AF)), treatment information (regimen, dose, 
duration), and outcome data (number of events for each 
outcome). Since all outcomes of interest were binary, the 
2*2 tables for each outcome were extracted. If multiple 
arms of the same drug at different doses were included in 
the same trial, the arms were combined into a single arm. 
This method is recommended in the Cochrane handbook 
[23] and was adopted in our previous meta-analysis [25]. 
When multiple studies of the same trial were found, the 
most updated publication/record was included. Data on 
outcomes of interest reported as SAEs on ClinicalTri-
als.gov were retrieved; data from the original trial pub-
lication or secondary analyses of the same trial were 
retrieved if no data could be extracted from ClinicalTri-
als.gov.
To assess methodological quality, the Cochrane Collab-
oration’s tool for assessing risk of bias was used [26]. Bias 
was assessed from seven domains: random sequence gen-
eration, allocation concealment, blinding of participants 
and personnel, blinding of outcome assessment, incom-
plete outcome data, selective reporting, and other biases. 
In each domain, bias was judged as high, low, or unclear. 
The overall risk of bias was judged as high if any domain 
was judged as high, as low if all domains were judged as 
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low, or as unclear otherwise. The certainty of evidence 
was assessed using the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) 
[27].
Study selection, data extraction, and quality assess-
ment were conducted by two independent authors (HLL, 
and BMYC). Any disagreement was resolved by discus-
sion until consensus was reached, or by consulting a third 
author (KHY).
Data synthesis and analysis
The placebo arm was defined as the control in all anal-
yses. Intention-to-treat analysis was employed. Rela-
tive risks (RR) and their 95% confidence intervals (CI) 
were pooled using a random-effects model with inverse 
variance weighting. RR < 1 would favor SGLT2i over 
placebo. Subgroup analysis was prespecified accord-
ing to the baseline condition (HF vs DM vs CKD), pres-
ence of ASCVD at baseline, the SGLT2i agent used, and 
follow-up duration (≤ vs > median follow-up duration 
of all trials). Additional sensitivity analyses were per-
formed by excluding studies with a high/unclear overall 
risk of bias, by excluding studies with a high/unclear bias 
in ‘Incomplete outcome data’, and by using odds ratio 
(OR) as the effect measure. To minimize the unbalanced 
representativeness of DM-only trials, a sensitivity analy-
sis stratifying trials into DM versus other baseline con-
ditions was performed. Statistical heterogeneity across 
studies was assessed by the Cochrane’s Q test and the 
 I2 statistic. If substantial heterogeneity, as suggested by 
a p-value < 0.10 or  I2 > 50%, was identified, meta-regres-
sion would be used to investigate potential sources of 
heterogeneity. Funnel plots were used for assessment of 
publication bias, and Egger’s test for asymmetry in fun-
nel plot would only be performed if 10 or more stud-
ies were included [23]. Asymmetries in the funnel plots 
determined by visual assessment or a p-value for Egger’s 
test < 0.10 would suggest potential publication bias, and a 
trim-and-fill method was employed to adjust for poten-
tial bias. The statistical significance level was defined at 
0.05 unless otherwise specified. Data analyses were per-
formed using the “meta” package in R (version 3.6.3).
Results
Among the 4,532 citations identified by literature search, 
22 trials [28–49] with altogether 52,115 patients (29,211 
on SGLT2i and 22,904 on placebo) were included. The 
PRISMA flow diagram is shown in Fig.  1. The mean 
age was 63.2 years and 64.8% were male (Table  1). The 
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Fig. 1 PRISMA flow diagram
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4.2). Seventeen trials enrolled patients with DM [28–44], 
three trials enrolled patients with DM and CKD [45–47], 
and two trials enrolled patients with HF [48, 49]. Over-
all, the percentages of the included participants with DM, 
CKD, and HF were 94.6%, 53.0% and 21.4%, respectively. 
The mean percentage of patients with a history of AF was 
10.2% (range 5.5% to 70.9%). Eleven trials had a low risk 
of bias [32, 34–36, 39, 44–49], six trials had a high risk of 
bias [28, 29, 31, 33, 37, 43], and five trials had an unclear 
risk of bias [30, 38, 40–42] (Additional file 1: Table S3).
In total, 590 and 17 events of AF and embolic stroke 
were reported as SAEs, respectively. The RRs for 
AF ranged from 0.05 to 3.00, while RRs for embolic 
stroke ranged from 0.17 to 2.50. Overall, SGLT2i were 
associated with a 18% and 68% risk reduction in AF (RR 
0.82, 95% CI 0.70–0.96) and embolic stroke (RR 0.32, 95% 
CI 0.12–0.85) compared to placebo (Fig.  2a, b). There 
was no significant heterogeneity across trials (p = 0.94 
and p = 0.99 for AF and embolic stroke, respectively). In 
subgroup analysis according to the baseline condition 
(DM vs CKD vs HF), no significant between-subgroup 
heterogeneity was identified (p = 0.63 and p = 0.99 for 
AF and embolic stroke, respectively) (Table  2). Simi-
larly, there were no significant heterogeneity in subgroup 
analysis according to the presence of ASCVD (p = 0.16 
and p = 0.53 for AF and embolic stroke, respectively). 
In subgroup analysis according to the SGLT2i agent 
used, no significant between-subgroup heterogeneity 
Fig. 2 Forest plots of primary analysis
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Table 2 Results of subgroup analysis




RR (95% CI) Phetero
AF Overall 21 51,193 0.82 (0.70–0.96)
Baseline condition DM 16 44,896 0.84 (0.71–1.00) 0.63
CKD 3 1474 0.93 (0.18–4.68)
HF 2 4823 0.65 (0.40–1.07)
ASCVD No ASCVD 18 43,114 0.79 (0.67–0.94) 0.16
ASCVD present 3 8079 1.23 (0.69–2.19)
SGLT2i agent Canagliflozin 6 16,378 0.90 (0.65–1.26) 0.39
Dapagliflozin 7 25,090 0.75 (0.61–0.91)
Empagliflozin 7 9258 1.19 (0.68–2.08)
Ertugliflozin 1 467 1.48 (0.06–36.08)
Follow‑up duration  ≤ 1 year 11 4916 0.82 (0.69–0.97) 0.90
 > 1 year 10 42,677 0.82 (0.70–0.96)
Embolic stroke Overall 6 44,205 0.32 (0.12–0.85)
Baseline condition DM 4 38,723 0.32 (0.10–1.03) 0.99
CKD 1 4401 0.25 (0.01–6.21)
HF 1 4744 0.25 (0.03–3.20)
ASCVD No ASCVD 5 37,185 0.37 (0.12–1.10) 0.53
ASCVD present 1 7020 0.17 (0.02–1.59)
SGLT2i agent Canagliflozin 2 14,543 0.29 (0.03–2.77) 0.78
Dapagliflozin 3 21,904 0.43 (0.11–1.68)
Empagliflozin 4 7758 1.19 (0.03–1.21)
Follow‑up duration  ≤ 1 year 1 738 0.25 (0.01–6.21) 0.89
 > 1 year 5 43,467 0.32 (0.12–0.92)
AFL Overall 9 45,478 0.83 (0.58–1.17)
Baseline condition DM 6 36,333 0.75 (0.52–1.09) 0.19
CKD 1 4401 1.00 (0.14–7.08)
HF 1 4744 2.66 (0.71–10.03)
ASCVD No ASCVD 6 37,439 0.91 (0.55–1.48) 0.90
ASCVD present 3 8039 0.97 (0.36–2.66)
SGLT2i agent Canagliflozin 2 14,543 1.08 (0.56–2.10) 0.95
Dapagliflozin 3 22,826 0.91 (0.28–3.00)
Empagliflozin 4 8109 1.14 (0.45–3.03)
Follow‑up duration  ≤ 1 year 2 1019 0.33 (0.01–8.20) 0.56
 > 1 year 7 44,459 0.87 (0.59–1.29)
AF/AFL Overall 22 49,115 0.82 (0.71–0.95)
Baseline condition DM 17 41,686 0.82 (0.70–0.97) 0.99
CKD 3 5606 0.83 (0.46–1.51)
HF 2 4823 0.79 (0.51–1.24)
ASCVD No ASCVD 18 40,114 0.79 (0.68–0.93) 0.16
ASCVD present 4 9001 1.16 (0.70–1.91)
SGLT2i agent Canagliflozin 6 16,378 0.94 (0.70–1.26) 0.20
Dapagliflozin 8 26,012 0.74 (0.62–0.89)
Empagliflozin 7 9258 1.21 (0.74–1.97)
Ertugliflozin 1 467 1.48 (0.06–36.08)
Follow‑up duration  ≤ 1 year 12 5838 0.73 (0.31–1.71) 0.78
 > 1 year 10 42,677 0.82 (0.71–0.96)
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was identified (p = 0.39 and p = 0.78 for AF and embolic 
stroke, respectively). There were no significant heteroge-
neity in subgroup analysis according to follow-up dura-
tion (p = 0.90 and p = 0.89 for AF and embolic stroke, 
respectively). 
A total of 135 events of AFL were reported as SAEs. The 
RRs for AFL ranged from 0.33 to 2.66. Overall, SGLT2i 
did not significantly influence the risk of AFL (RR 0.83, 
95% CI 0.68–1.17) compared to placebo (Fig. 2c). There 
was no significant heterogeneity across trials (p = 0.45). 
In subgroup analysis according to baseline condition, 
according to the presence of ASCVD, according to the 
SGLT2i agent used, and according to follow-up duration, 
no significant between-subgroup heterogeneity was iden-
tified (p = 0.19, p = 0.90, p = 0.95, and p = 0.56, respec-
tively) (Table 2).
When AF and AFL are combined as a composite end-
point, SGLT2i are associated with an 18% risk reduction 
in AF/AFL (RR 0.82, 95% CI 0.71–0.95) (Fig. 2d). There 
was no significant heterogeneity across trials (p = 0.90). 
Subgroup analysis stratifying studies according to 
baseline condition, presence of ASCVD, SGLT2i agent, 
and follow-up duration did not identify a significant 
between-subgroup heterogeneity (p = 0.99, p = 0.16, 
p = 0.20, and p = 0.78, respectively) (Table 2).
A total of 163 events of VT were reported as SAEs. The 
RRs for VT ranged from 0.33 to 3.00. Overall, SGLT2i 
were associated with a 27% risk reduction in VT com-
pared to placebo (RR 0.73, 95% CI 0.53–0.99) (Fig.  2e). 
There was no significant heterogeneity across trials 
(p = 0.61). Subgroup analysis stratifying studies accord-
ing to baseline condition, presence of ASCVD, SGLT2i 
agent, and follow-up duration did not identify a signifi-
cant between-subgroup heterogeneity (p = 0.50, p = 0.30, 
p = 0.48, and p = 0.79, respectively) (Table 2).
A total of 157 cardiac arrest events were reported as 
SAEs. The RRs for cardiac arrest ranged from 0.07 to 
1.06. Overall, SGLT2i did not significantly influence 
the risk of cardiac arrest (RR 0.83, 95% CI 0.61–1.14) 
(Fig.  2f ). There was no significant heterogeneity across 
trials (p = 0.44). Subgroup analysis according to base-
line condition, presence of ASCVD, SGLT2i agent, and 
Table 2 (continued)




RR (95% CI) Phetero
VT Overall 7 43,963 0.73 (0.53–0.99)
Baseline condition DM 4 34,739 0.90 (0.56–1.42) 0.50
CKD 1 2501 0.50 (0.05–5.50)
HF 2 4823 0.62 (0.41–0.95)
ASCVD No ASCVD 6 36,846 0.77 (0.56–1.06) 0.30
ASCVD present 2 7117 0.44 (0.16–1.20)
SGLT2i agent Canagliflozin 2 14,543 0.80 (0.28–2.32) 0.48
Dapagliflozin 3 22,224 0.82 (0.50–1.33)
Empagliflozin 3 7196 0.42 (0.16–1.11)
Follow‑up duration  ≤ 1 year 3 496 0.98 (0.10–9.29) 0.79
 > 1 year 5 43,647 0.72 (0.53–0.99)
Cardiac arrest Overall 7 44,751 0.83 (0.61–1.14)
Baseline condition DM 4 34,868 0.74 (0.42–1.30) 0.93
CKD 2 5139 0.72 (0.25–2.08)
HF 1 4744 0.90 (0.37–2.21)
ASCVD No ASCVD 6 37,731 0.92 (0.66–1.30) 0.12
ASCVD present 1 7020 0.46 (0.20–1.03)
SGLT2i agent Canagliflozin 2 14,543 0.85 (0.46–1.52) 0.44
Dapagliflozin 3 22,450 0.88 (0.44–1.75)
Empagliflozin 2 7758 0.48 (0.22–1.04)
Follow‑up duration  ≤ 1 year 1 738 0.76 (0.05–12.13) 0.97
 > 1 year 6 44,013 0.81 (0.56–1.16)
AF atrial fibrillation, AFL atrial flutter, VT ventricular tachycardia, RR risk ratio, 95% CI 95% confidence interval, Phetero P-value for between-subgroup heterogeneity, DM 
diabetes mellitus, CKD chronic kidney disease, HF heart failure, ASCVD atherosclerotic cardiovascular disease
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follow-up duration did not identify a significant between-
subgroup heterogeneity (p = 0.93, p = 0.12, p = 0.44, and 
p = 0.97, respectively) (Table 2).
Sensitivity analyses excluding studies with a high/
unclear overall risk of bias, excluding studies with a high/
unclear risk of bias in Incomplete outcome data, and 
using OR as an effect measure yielded largely consistent 
results (Additional file 1: Table S4(A)). In the sensitivity 
analysis stratifying trials according to DM versus other 
baseline conditions (CKD or HF), there were no signifi-
cant subgroup differences (Additional file 1: Table S4(B)). 
Symmetry was observed in the funnel plots for AF, 
embolic stroke, AF/AFL, VT, and cardiac arrest, but not 
for AFL (Additional file 1: Fig. S1). Egger’s test for AF and 
AF/AFL did not reveal significant asymmetry, whereas 
Egger’s test was not performed for embolic stroke, AFL, 
VT, and cardiac arrest since the number of studies was 
below 10. Trim-and-fill method generated an overall RR 
of 0.77 (95% CI 0.52–1.14) for AFL. The GRADE assess-
ment for each outcome was shown in Additional file  1: 
Table  S5. The certainty of evidence for AF, embolic 
stroke, AF/AFL, and VT were graded as high, whereas 
the certainty for AFL and cardiac arrest were graded as 
moderate due to imprecision (as the 95% of the relative 
risk was sufficiently wide that the estimate could include 
appreciable benefit/harm of the use of SGLT2i, with 0.75 
and 1.25 taken as thresholds).
Discussion
In this systematic review and meta-analysis of 22 trials 
with 52,115 patients with DM, CKD, or HF susceptible to 
developing arrhythmias, we found that SGLT2i treatment 
might be associated with a lower risk of AF, embolic 
stroke, AF/AFL, and VT, compared to placebo. The asso-
ciations appeared to be consistent across all baseline 
conditions (HF vs DM vs CKD; ASCVD vs no ASCVD), 
all SGLT2i subgroups, and across short vs long follow-
up duration. Although no significant associations were 
observed for AFL and cardiac arrest, the point estimates 
appeared to be consistent with that of AF. These findings 
are consistent with recent reports suggesting that SGLT2i 
reduced the risk of arrhythmias [17, 20].
To the authors’ knowledge, this is the largest and most 
comprehensive systematic review and meta-analysis that 
addresses the association between SGLT2i and arrhyth-
mia outcomes.
A previous meta-analysis did not find a significant 
association between SGLT2i treatment and AF (OR 0.61, 
95% CI 0.31–1.19) [18]. As the number of participants 
(52,115 vs 10,512) and events (590 vs 30) are much larger 
in our meta-analysis, the association we identified, which 
suggests a significant risk reduction in AF with SGLT2i 
treatment, is more likely to be robust. In the EMPA-REG 
OUTCOME trial, although the incidence of new-onset 
AF appeared to be higher in the SGLT2i group (2.3%) 
than in the placebo group (1.6%), the difference did not 
reach statistical significance [19]. Furthermore, no sig-
nificant difference between SGLT2i subgroups was iden-
tified in our meta-analysis. Previous meta-analyses have 
identified consistent risk reductions in adverse cardio-
vascular/renal events across different SGLT2i agents, and 
empagliflozin is likely to exhibit similar cardio- and reno-
protective properties [14, 50]. Nevertheless, a recent 
real-world cohort study of patients with DM found that 
empagliflozin resulted in poorer outcome in reduction 
of HF compared to dapagliflozin [51]. Therefore, larger 
studies evaluating the effects of empagliflozin on AF are 
required to confirm the association.
A previous meta-analysis found that SGLT2i did not 
significantly influence the risk of stroke [52]. However, 
embolic stroke was not specifically studied as an out-
come. No previous studies have evaluated the associa-
tion between SGLT2i and embolic stroke, and the current 
meta-analysis is the first to report the protective effect 
of SGLT2i on embolic stroke. Such association might 
be attributed to the risk reduction in AF. Neverthe-
less, owing to the low number of events reported in the 
included trials, larger studies evaluating the association 
between SGLT2i and embolic stroke are needed to con-
firm our findings.
Although our meta-analysis failed to identify a signifi-
cant risk reduction in AFL, a statistically significant risk 
reduction was identified when AF and AFL were evalu-
ated as a composite outcome. A similar risk reduction in 
AF/AFL events (RR 0.81, 95% CI 0.67–0.98) was identi-
fied in the secondary analysis of the DECLARE-TIMI 58 
trial [17]. The low number of AFL events observed in the 
included trials in our meta-analysis might have contrib-
uted to a wide confidence interval, hence a marginally 
significant association. Larger RCTs powered to detect 
differences in AFL are required to confirm these findings. 
Nevertheless, AF and AFL have similar clinical signifi-
cance and consequences, [53] and the conjoint analysis 
of AF/AFL, which shows a significant risk reduction, pro-
vides more robust results while obviating possible publi-
cation bias for AFL.
A previous meta-analysis by Li et  al. identified a 24% 
risk reduction in AF/AFL with SGLT2i treatment, [54] 
as compared to 18% and 17% risk reduction in AF and 
AFL, respectively, in our meta-analysis. The inconsist-
ency could be explained by the significant methodo-
logical differences. In addition to trials of DM patients, 
our meta-analysis also included trials of HF and CKD 
patients, resulting in a significantly higher number of tri-
als (22 vs 16) and patients (52,115 vs 38,335) included. 
Therefore, our observations are likely to be more robust 
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and accurate. More importantly, as the use of SGLT2i 
has greatly expanded from selected DM patients only 
to patients with DM, CKD, and cardiovascular diseases, 
[55] our findings are applicable to patients with a much 
broader spectrum of comorbidities. Furthermore, the 
meta-analysis by Li et  al. only evaluated AF/AFL as an 
arrhythmia outcome, as compared to four additional out-
comes (AF, embolic stroke, AFL, VT, and cardiac arrest) 
evaluated in our meta-analysis, highlighting the compre-
hensiveness of the present study. Our meta-analysis pro-
vides a more holistic evaluation of how SGLT2i reduced 
the risk of arrhythmias.
The association between SGLT2i, VT, and cardiac 
arrest has been less well studied. To our knowledge, this 
meta-analysis is the first study to address this research 
question. SGLT2i treatment was associated with a 28% 
risk reduction for VT. In the recent EMBODY trial, [56] 
improvements in indicators of cardiac sympathetic/
parasympathetic nerve activity, which are related to the 
risk of ventricular tachyarrhythmias, were greater in the 
empagliflozin group compared to the placebo group. 
Only the empagliflozin group achieved a significant intra-
group improvement. Taking these findings together, it is 
likely that SGLT2i may exert a protecting effect against 
VT. Meanwhile, six out of seven studies reported an RR 
of < 1.0 for cardiac arrest, and there was a 17% risk reduc-
tion in developing cardiac arrest. The marginally signifi-
cant association could be attributed to a low number of 
events, and larger prospective studies are warranted to 
confirm the association.
It is being increasingly recognized that HF, DM, and 
CKD are associated with AF and cardiac arrhythmias 
[1–4, 9]. The presence of AF is associated with a higher 
risk of adverse cardiovascular events, cardiovascular 
mortality, and all-cause mortality in individuals with 
HF, CKD, and DM [2, 4, 7–9]. Similar associations were 
observed for AFL and VT: HF and DM may predispose to 
the development of AFL and VT, which are in turn asso-
ciated with higher mortality [10–12]. Therefore, it is of 
critical importance to reduce the risk of arrhythmias in 
patients with HF, DM, and CKD.
The pathophysiological pathways linking DM, CKD, 
and HF with the development of AF and arrhythmias are 
complex and multifactorial [2, 3, 6]. The presence of DM 
has been implicated to explain the coexistence of CKD, 
HF, and AF [3, 4]. Compared to the general population, 
individuals with DM and stage 5 CKD have a threefold 
increased risk to develop AF, [5] in which comorbid DM 
increases the risk of bleeding in patients with AF [57]. 
DM has also been found to increase the risk of subopti-
mal response to cardiac resynchronization therapy with 
defibrillator in patients with HF [58]. Furthermore, mul-
tiple signaling pathways contribute to remodeling and 
arrhythmogenic properties in HF, increasing the risk of 
developing ventricular tachyarrhythmias [9, 59]. There 
are also several possible mechanisms through which 
SGLT2i reduce the risk of arrhythmias. By promoting 
osmotic diuresis and natriuresis, SGLT2i alleviate car-
diac workload and improve left ventricular function [60]. 
SGLT2i may also reduce arrhythmia by modulating neu-
rohormonal pathways, which, in DM, CKD, and HF, are 
activated and play important roles in the deterioration of 
these conditions [61, 62]. By optimizing hemodynamic 
status, SGLT2i reduce fluid overload, which is associated 
with cardiac structural abnormalities, hence predisposi-
tion to arrhythmia, in DM and CKD [63]. SGLT2i are also 
effective in blood pressure and glycemic control, both 
of which are implicated in cardiac arrhythmogenesis 
[64]. Furthermore, by inhibiting the myocardial sodium-
hydrogen exchanger  (Na+/H+ exchanger), which is 
upregulated in HF, SGLT2i lead to improvement in mito-
chondrial dysfunction and reduction in oxidative stress, 
thus reducing the risk of arrhythmias [65, 66]. Apart from 
improving mitochondrial function, [67] SGLT2i have 
also been found to alleviate atrial remodeling, an impor-
tant process implicated in atrial arrhythmogenesis [68]. 
SGLT2i may also reduce electrical instability by ensuring 
a sufficient energy supply [69–71]. Other possible mecha-
nisms are outlined in Additional file 1: Fig. S2.
There are several limitations in this meta-analysis. 
First, arrhythmia outcomes were not the pre-specified 
outcomes of the included trials, and there might be 
ascertainment bias. The outcomes were not adjudicated 
and might lead to inaccuracies and incompleteness of 
data. Nevertheless, in sensitivity analyses where studies 
with high/unclear overall risk of bias and studies with 
high/unclear risk of bias in ‘Incomplete outcome data’ 
were excluded, largely consistent associations were 
observed. Nevertheless, the approach of using adverse 
events as outcomes has been used in previous studies 
[21, 54]. Nonetheless, further randomized trials with 
well-defined and adjudicated arrhythmia outcomes 
are required to confirm the associations reported in 
the current study. Second, the included trials were 
underpowered to detect differences in arrhythmia out-
comes. Future trials designed with arrhythmias as the 
primary outcomes are warranted. Third, outcomes on 
arrhythmia-related mortality were not included. These 
outcomes are clinically more important but were not 
reported in the identified trials. AF confers higher mor-
tality in patients with DM, CKD, and HF, and further 
studies examining the effects of SGLT2i on arrhythmia-
related death are urgently needed. Fourth, as patient-
level data were not available and not all trials reported 
the baseline prevalence of DM/CKD/HF, trials could 
not be grouped according to a combination of disease 
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processes, for instance, DM + CKD + HF. Therefore, 
further studies are required to evaluate whether SGLT2 
inhibitors could reduce incidences of arrhythmia in 
patients with multiple comorbidities. Fifth, as no data 
on the number of events specific to baseline comorbid-
ity, for instance, the number of AF events in those with 
pre-existing HF vs those without, were available from 
the trial, the results of subgroup analyses should be 
interpreted with caution, and further studies are war-
ranted to confirm that the associations between SGLT2i 
and arrhythmias remain significant regardless of the 
presence of baseline comorbidity. Sixth, patient-level 
data on pre-existing AF and the use of anti-arrhythmic 
medications were not available from most trials.
Conclusions
This meta-analysis found that SGLT2i reduced the risk 
of AF and VT. Our study provides further robust evi-
dence for recommending the use of SGLT2i in patients 
with DM, CKD, and HF to reduce related cardiac com-
plications and comorbidities. However, the mecha-
nisms by which SGLT2i protects against arrhythmias 
are complex and further research is warranted.
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